Non-responders of anti-VEFG treatments for AMD identify certain genetic variants in the VEGF pathway

Researchers at the Department of Ophthalmology at Ghent University Hospital have reported that the identification of genetic variants from wet AMD patients do not provide benefit for anti-VEFG treatments (ranibizumab and bevacizumab).  The researchers identified several SNPs (single nucleotide polymorphisms) associated with anti-VEFG treatments that did not respond to drug therapy, particularly three genes – FLT4, KDR and VEGFC.  As there is a significant proportion of patients that do not respond to such treatment, other strategies may need to address alternative anti-VEGF treatments, or require other novel targets for drug development.


It is estimated that about 10%-20% of wet AMD patients fail to respond anti-VEGF medication and this provides a significant challenge given that the wet AMD population could reach an estimated 2M patients by 2050.  The current clinical research has recently aimed to identify a common tagging SNP study in genes encoding VEGF pathway components from 281 patients treating anti-VEGF treatment. The association of genotypes with treatment response showed seven SNPs with a significant association with treatment outcome after 3 months, and 10 SNPs with outcome after 12 months. The primary outcome measure of the change in central foveal thickness (CFT) was at 3 months after treatment onset.  Seven SNPs were identified, including three genes – FLT4 (s7691507), KDR (rs2305945) and VEFGC. Only association with rs55667289 in FLT4 appeared to survive multiple testing correction.   FLT4 is encoded by VEGF receptor 3 (a tyrosine kinase receptor of VEGFC and VEGFD) and this was previously linked to a reduced response to sunitinib in clear cell renal cell carcinoma.


According to the research, the study in the report suggested that “neovascularisation in these non-responsive patients could be driven by angiogenic pathways other than the VEGF pathway”.   There could be other pathways in the current pathophysiology or rare genetic lesions that are not yet clearly identified.  In addition, there may be additional anti-VEGF treatments to capture other non-responder populations outside this study, including aflibercept, abicipar pegol or brolucizumab, and other agents not yet approved.

9 thoughts on “Non-responders of anti-VEFG treatments for AMD identify certain genetic variants in the VEGF pathway”

  1. I get pleasure from, result in I found just what I used to be taking a look for.
    You’ve ended my four day lengthy hunt! God Bless you
    man. Have a great day. Bye

  2. Hello there, I found your web site by the use of Google
    at the same time as looking for a similar subject, your web site got
    here up, it seems good. I have bookmarked it in my google bookmarks.

    Hi there, just was alert to your blog thru Google, and located that it’s truly
    informative. I am going to watch out for brussels.
    I will appreciate should you proceed this in future.
    Many people will likely be benefited from your writing.

  3. Have you ever thought about creating an e-book or guest authoring on other
    sites? I have a blog based upon on the same subjects you discuss and would really like to
    have you share some stories/information. I know my
    audience would value your work. If you’re even remotely interested, feel free to shoot me an email.

  4. I just want to mention I am just all new to weblog and actually savored you’re blog. Very likely I’m want to bookmark your blog post . You actually come with beneficial well written articles. Regards for sharing your blog site.

  5. I?m pleased, I have to say. Truly seldom do I run into a blog site that?s both informative and enjoyable, as well as let me tell you, you have actually hit the nail on the head. Your idea is exceptional; the concern is something that inadequate individuals are talking intelligently around. I am really delighted that I stumbled across this in my search for something associating with this.

  6. I really got into this article. I found it to be interesting and loaded with unique points of interest. I like to read material that makes me think. Thank you for writing this great content.

  7. Imagine anyone learned a method involving generating quite a bit regarding money on the net. Ever subsequently offer to make sure everybody about your own ‘secret formula’? I don’t even think thus! You’ll no doubt run into individuals who will try in order to persuade an individual they want found such a formula, no question provide to talk about that on hand. Trust me personally the item costs, not simply on a financial basis nevertheless within thrown away moment far too. Generally shy absent you may notice the word ‘Secrets’, and also discover delivers associated with substantial profits!

  8. When I originally commented I clicked the -Alert me when new remarks are added- checkbox and now each time a remark is added I get 4 e-mails with the same remark. Is there any way you can remove me from that service? Many thanks!

  9. An outstanding share, I simply given this onto a coworker who was doing a little analysis on this. And also he in fact purchased me morning meal due to the fact that I discovered it for him. smile. So let me reword that: Thnx for the reward! But yeah Thnkx for spending the time to discuss this, I feel highly regarding it and enjoy reading more on this topic. Ideally, as you come to be know-how, would you mind upgrading your blog site with even more details? It is very helpful for me. Big thumb up for this article!

Leave a Reply

Your email address will not be published.